Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. - Wikidata - wikimedia - TriplyDB

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

http://www.wikidata.org/entity/Q51987968

about

Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use Alemtuzumab for Multiple Sclerosis.Alemtuzumab for the treatment of multiple sclerosis Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS).Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis.Alemtuzumab therapy for multiple sclerosis.Efficacy and safety of alemtuzumab in multiple sclerosis and impact on nursing role.Promising treatments of tomorrow for multiple sclerosis.T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.Risk stratification and mitigation multiple sclerosis.Safety of monoclonal antibodies for the treatment of multiple sclerosis.IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)Low-intensity transplant regimens facilitate recruitment of donor-specific regulatory T cells that promote hematopoietic engraftment.ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.Listeria monocytogenes infection associated with alemtuzumab - - a case for better preventive strategies.What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.Immunodeficiency and autoimmunity in 22q11.2 deletion syndrome.CD4+FOXP3+ Regulatory T-Cell Subsets in Human Immunodeficiency Virus Infection.Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT The complex genetics of multiple sclerosis: pitfalls and prospects Treating multiple sclerosis with monoclonal antibodies.Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab.Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation.Emerging immunopharmacological targets in multiple sclerosis.Alemtuzumab in the treatment of multiple sclerosis.

P2860

Q26771459-82D670FF-2FE5-4713-BE3F-9FBFE5D16434 Q26776234-AC62A0D4-176A-4ABD-A1AC-34E3953BD594 Q26800128-B54BCE6D-19AA-4EC7-BFE0-0EB58EEAA699 Q26849781-7E428099-0ABF-48F0-97E8-5557D1B27B98 Q28069730-CABBFF2C-0113-4A4B-99CF-9853925CDA7B Q28080506-3DE54F9F-37E4-4B65-81B0-3ACD897EACEB Q28087414-D6ED0397-B2D7-4DC8-B851-F88A98081288 Q28260587-54814525-6306-4C96-825B-648015F71BA9 Q29618394-EF811667-0CA9-4EA4-BEB4-103FF9E17E16 Q30458930-AF6A6B48-C11B-401E-A7D0-258BDD1DE268 Q30808014-98A26734-770F-475D-AD64-59F0C5B7708B Q31115496-71234AF3-C193-412C-83C3-64DD8BD1788A Q33395186-B4FB5C2B-C206-476E-8444-ECB501638C23 Q33404568-592B9FD8-11C5-4625-BE33-F6AE218B26DB Q33412834-D0A9E6AF-0027-49BF-BDA4-0A690010D238 Q33670947-0AA717EC-EE3A-430D-B7C1-E50DEB648C68 Q33723154-A5C81E23-B255-4E1C-B80E-1EDE5AAEB896 Q33755345-4F75EAA3-5BAE-463C-B8AC-7AA8E2C5CB2A Q33961799-2A7CEF1D-3CE8-4315-B1AB-3277F82044E3 Q34155446-8589448A-A540-4DF8-B003-F9440E46D303 Q34542922-0D30FA15-B8E7-47DA-A440-40FAB98BEEFA Q34988311-ADF32DFD-FEE0-4BFA-BBC2-B8DD0EBCE135 Q35850195-3FAB6AEA-0D8B-4263-AEB0-7EF38C65D530 Q35953466-BCF87355-BC61-42D8-A5E4-8FAB272603B3 Q36334825-63EA2D27-1015-4B2F-AAF2-D204188D327D Q36396476-2C06FAD2-694A-4275-8FAA-C76B568AE7B3 Q36399264-8AA0576D-F4AE-4646-9CFC-E0EFB9E8C936 Q36672726-45D5D8D1-8650-4C01-A01D-08BC0873693F Q36857515-55B22F28-F814-4004-AA72-736A83D2AF99 Q37054806-28C207CA-4F34-4975-97E3-4E4B852BCC8D Q37066280-F35A81AF-1068-400D-915A-7495A17C790A Q37090601-201ADE46-2F66-493F-822C-289A1DE1BB23 Q37111904-7C238CCF-5F3D-4911-A6E9-90D8A6F3177E Q37124529-95E9058E-12CB-4F26-AE25-CB695B162040 Q37129671-02A96BD1-3E71-4E2D-A980-BEC0B8BA3604 Q37246752-C549420E-414D-4936-BE72-882EAF3EE982 Q37360536-3A587600-E504-4EEC-876A-DEA54B9BF909 Q37395089-17E46E8B-F9FB-476A-8D78-9E2522F04E4F Q37559970-3DA5FB79-25C9-4EFE-B2D7-E63CC2EBA6C0 Q37649028-57C1F6A3-2502-48FE-A8CB-2BE4AF4FD97E

P2860

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

http://www.wikidata.org/entity/Q51987968

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

@en

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

@nl

type

label

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

@en

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

@nl

prefLabel

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

@en

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

@nl

P1433

Q51987968-4E0DBB4A-6C31-492D-B783-D10080861A54

P1476

Q51987968-63C9ECE8-3C72-4E6F-ABA6-1ACEB2F1BE83

P2093

Q51987968-1B5D7FB2-418A-4943-9C7B-9CE59DA72ACB

Q51987968-34461190-33A2-4777-A60E-10052AA4E60B

Q51987968-9D4E31ED-07D7-4C90-9B2C-07F99A422E68

Q51987968-A20B665B-4FD3-41A0-8246-89EB06E071C0

Q51987968-CD9ECC72-9481-4EB4-92B7-F3E6B79C0A2E

Q51987968-E192A539-2EB1-4588-8B2F-ABBCDA364768

Q51987968-E587FAC0-7433-455B-8FA1-52010968CAC8

P2860

Q51987968-3AE8D55E-D5CD-46BD-A2B7-FE043859A0B9

Q51987968-706184B5-1047-4DD4-BE80-7CB36845AC69

Q51987968-C3DFEC44-B760-42BE-BE9D-0B5E7862C953

Q51987968-E1B5A92F-E730-46E2-B953-32BBBC3A23E4

P304

Q51987968-8F317121-DA87-4DDB-9711-BDE700C1E01F

P31

Q51987968-A883D7A2-22EC-415E-B1DE-1B63E2DF1E77

P356

Q51987968-41B1584D-9F70-4E77-B080-A068D152BDAC

P407

Q51987968-1712F45D-CEA5-4C59-B0B0-DB92D3D2643E

P433

Q51987968-1D4CCD1B-D1D7-4001-B54E-EA56F326828D

P478

Q51987968-C7BA534B-85E0-4EC6-AE48-6CDE75A26702

P50

Q51987968-23B383B1-2734-45F1-9CD3-8405B3FF9AE1

P577

Q51987968-7DD32247-260A-4754-B549-52A7D1FEE031

P5875

Q51987968-0252A88A-79DF-4A52-9B8A-A7FB9C092238

P698

Q51987968-98794EBD-CFE2-42D3-84B1-A619160839C6

P921

Q51987968-D099C51B-F227-47D1-B424-4D7FF75AC00C

P356

P1433

European Journal of Immunology

P1476

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

@en

P2093

Alasdair J Coles

http://www.w3.org/2001/XMLSchema#string

Amanda L Cox

http://www.w3.org/2001/XMLSchema#string

D Alastair S Compston

http://www.w3.org/2001/XMLSchema#string

Geoff Hale

http://www.w3.org/2001/XMLSchema#string

Joanne L Jones

http://www.w3.org/2001/XMLSchema#string

Sara A J Thompson

http://www.w3.org/2001/XMLSchema#string

Vicki H Robertson

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412

The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance.

A repressor of GATA-mediated negative feedback mechanism of T cell activation.

P304

3332-3342

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/EJI.200535075

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

Herman Waldmann

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7535709

http://www.w3.org/2001/XMLSchema#string

P698

16231285

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis